High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2198-6584
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame? ; volume:7 ; number:4 ; day:28 ; month:10 ; year:2020 ; pages:1011-1019 ; date:12.2020
Rheumatology and therapy ; 7, Heft 4 (28.10.2020), 1011-1019, 12.2020
- Creator
-
Perez-Ruiz, Fernando
Perez-Herrero, Nuria
Richette, Pascal
Stack, Austin G.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40744-020-00249-w
- URN
-
urn:nbn:de:101:1-2021010719261764625328
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 3:39 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Perez-Ruiz, Fernando
- Perez-Herrero, Nuria
- Richette, Pascal
- Stack, Austin G.
- SpringerLink (Online service)
Other Objects (12)
Variation in serum urate levels in the absence of gout and urate lowering therapy
Who's to blame?
Who's to blame?
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
Adherence with urate-lowering therapies for the treatment of gout
Factors associated with initiation and persistence of urate-lowering therapy
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Development and usability of a web-based patient-tailored tool to support adherence to urate-lowering therapy in gout
Who’s to blame for island disputes in the western Pacific? Thomas Jefferson, a Dutch teenager, and Ecuador. Obviously
Effects of Conventional Uric Acid–Lowering Therapy on Monosodium Urate Crystal Deposits
Agency - who is to blame?
Variation in serum urate levels in the absence of gout and urate lowering therapy
Who's to blame?
Who's to blame?
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
Adherence with urate-lowering therapies for the treatment of gout
Factors associated with initiation and persistence of urate-lowering therapy
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Development and usability of a web-based patient-tailored tool to support adherence to urate-lowering therapy in gout
Who’s to blame for island disputes in the western Pacific? Thomas Jefferson, a Dutch teenager, and Ecuador. Obviously
Effects of Conventional Uric Acid–Lowering Therapy on Monosodium Urate Crystal Deposits
Agency - who is to blame?
Variation in serum urate levels in the absence of gout and urate lowering therapy
Who's to blame?
Who's to blame?
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
Adherence with urate-lowering therapies for the treatment of gout
Factors associated with initiation and persistence of urate-lowering therapy
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Development and usability of a web-based patient-tailored tool to support adherence to urate-lowering therapy in gout
Who’s to blame for island disputes in the western Pacific? Thomas Jefferson, a Dutch teenager, and Ecuador. Obviously
Effects of Conventional Uric Acid–Lowering Therapy on Monosodium Urate Crystal Deposits